Budesonide vs mesalamine in isolated jejunal CD

no retrieved study answers this specific comparison in isolated jejunal crohn's. at the level of mild-to-moderate crohn's overall, a cochrane meta-analysis found budesonide 9 mg/day significantly more effective than mesalamine for inducing remission at 8 weeks (RR 1.63, 95% CI 1.23–2.16) ¹, but this pooled estimate is not stratified by jejunal disease location and does not specify the 2.4 g/day mesalamine dose you name. ¹

What is known:

• A meta-analysis concluded budesonide was significantly more effective than mesalamine for induction of remission at 8 weeks (RR 1.63, 95% CI 1.23–2.16). ¹
• Budesonide 9 mg/day for 8 weeks induced remission in roughly 48–51% of active crohn's patients versus placebo across two trials. ¹
• Short-term budesonide efficacy is lower than conventional steroids, particularly with severe or more extensive colonic involvement. ¹

What is unknown / caveats:

• No retrieved study isolates jejunal crohn's disease location
• The pooled comparison does not specify mesalamine 2.4 g/day
• Budesonide's ileal-release formulation targets ileocolonic disease. Proximal jejunal efficacy is not addressed in the excerpts
• The corpus does not contain a head-to-head trial in jejunal-limited crohn's at these specific doses.

References

1. O'Donnell S, O'Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1:177-86. PMID: 23251737.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.